EU indices slightly up | TA focus on AstraZeneca

,

European stocks report | AstraZeneca | BNP Paribas | Altice Europe...

Stocks (2)

INDICES
Yesterday, European stocks were broadly lower. The Stoxx Europe 600 fell 0.75%, Germany's DAX lost 0.88%, France's CAC 40 dropped 0.67%, and the U.K.'s FTSE 100 was down 0.80%.

EUROPE ADVANCE/DECLINE
72% of STOXX 600 constituents traded lower or unchanged yesterday.
82% of the shares trade above their 20D MA vs 84% Wednesday (above the 20D moving average).
83% of the shares trade above their 200D MA vs 85% Wednesday (above the 20D moving average).

The Euro Stoxx 50 Volatility index added 1.07pt to 21.97, a new 52w high.

SECTORS vs STOXX 600
3mths relative high: Autos
3mths relative low: none

Europe Best 3 sectors
retail, energy, basic resources

Europe worst 3 sectors
banks, automobiles & parts, insurance



INTEREST RATE
The 10yr Bund yield rose 1bp to -0.55% (above its 20D MA). The 2yr-10yr yield spread rose 1bp to -16bps (above its 20D MA).


ECONOMIC DATA
UK 01:01: Nov GfK Consumer Confidence, exp.: -31
GE 08:00: Oct PPI YoY, exp.: -1%
GE 08:00: Oct PPI MoM, exp.: 0.4%
UK 08:00: Oct Public Sector Net Borrowing, exp.: £-36.1B
UK 08:00: Oct Retail Sales ex Fuel MoM, exp.: 1.6%
UK 08:00: Oct Retail Sales ex Fuel YoY, exp.: 6.4%
UK 08:00: Oct Retail Sales YoY, exp.: 4.7%
UK 08:00: Oct Retail Sales MoM, exp.: 1.5%
GE 14:00: Bundesbank Weidmann speech
EC 16:00: Nov Consumer Confidence Flash, exp.: -15.5

MORNING TRADING
In Asian trading hours, EUR/USD was little changed at 1.1875 and GBP/USD was broadly flat at 1.3265. USD/JPY edged up to 103.82. AUD/USD remained subdued at 0.7289. This morning, official data showed that Australia's preliminary retail sales grew 1.6% on month in October (-1.1% in September).

Spot gold slipped to $1,864 an ounce.


#UK - IRELAND#
AstraZeneca, a pharmaceutical group, said its "Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer".
From a technical point of view, the stock has escaped from a falling wedge in place since June 2020. Despite the recent pullback, as long as 7770p is support look for 8800p and the previous all-time high at 10120p. Alternatively, a break below 7770p should be limited by a rising long term trend line.


Source: TradingView, GAIN Capital

#GERMANY#
Talanx, a financial services company, was downgraded to "hold" from "buy" at HSBC.


#FRANCE#
BNP Paribas, a banking group, may sell its Italian payments unit Axepta for 200 million euros, reported Bloomberg citing people familiar with the matter.


#BENELUX#
Altice Europe, a telecommunications corporation, announced that 3Q adjusted EBITDA grew 5.1% on year to 1.48 billion euros on revenue of 3.77 billion euros, up 3.2% (+4.1% at constant currency).


#SWITZERLAND#
ABB, an automation technology company, was downgraded to "sell" from "hold" at Deutsche Bank.

Swatch Group, a manufacturer of watches and jewellery, was downgraded to "hold" from "buy" at HSBC.

More from Equities

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.